Qiang “Shawn” Chenis an ASU Biodesign Institute researcher and School of Life School Sciences professor, Center for Infectious Diseases and Vaccinology.
The ARIZONA INNOVATION CHALLENGE (AIC) Spring 2016 Round Opens Monday February 8,2016. Up to 6 Companies will Win Up to $250,000 each.Continue reading
The FDA approved the first biosimilar in the U.S. in March of 2015 with more expected to be approved in 2016. Now, on a state by state basis, the laws that govern how these new therapies can be dispensed are being updated. Arizona has the opportunity to do so in 2016 with HB 2310 sponsored by Dr. Regina Cobb, Vice Chairman of the House Health Committee.Continue reading
Flagship Biosciences created a Clinical Trials and Regulatory Affairs Group and partners with DOCRO, Inc., an industry leader for IVD clinical trials and regulatory affairs, to bring image analysis based Companion Diagnostics (CDx) into the clinical market. Continue reading
Historic National Coalition formed to accelerate next generation immunotherapy in cancer careContinue reading
Dr. Joshua L. LaBaer, named interim executive director for the Biodesign Institute at Arizona State University.
Study funded by Ivy Foundation shows SGEF plays roles in how cancer cells survive and invade brain tissueContinue reading
SUCAMPO ENTERS INTO EXCLUSIVE OPTION AND COLLABORATION AGREEMENT WITH CANCER PREVENTION PHARMACEUTICALS FOR DEVELOPMENT OF LATE-STAGE CPP-1X/SULINDAC COMBINATION FOR FAMILIAL ADENOMATOUS POLYPOSIS
Life science entrepreneur, investor,and philanthropist Peter N. Allison passed away unexpectedly in Scottsdale, AZ on December 22, 2015.Continue reading